Advertisement

Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study

      Abstract

      This study estimated the cumulative incidence and risk ratio for osteonecrosis of the jaw (ONJ) after tooth extraction in patients with and without administration of bisphosphonates (BP) and identified potential risk factors for bisphosphonate-induced osteonecrosis of the jaw (BIONJ). A cohort study was conducted in all patients undergoing tooth extraction at a university hospital in Japan from April 2006 to June 2009. Of 3216 patients, 126 had BP administration, of whom 5 (3.9%, 95% confidence interval (CI): 1.2–9.2) developed ONJ, versus 1 (0.032%, 95% CI: 0.00081–0.18) among 3090 patients without BP administration. BP administration was associated with the development of ONJ after tooth extraction, with an unadjusted risk ratio of 122.6 (95% CI: 14.4–1041.8). When stratified by age and route of BP administration, the risk ratio for ONJ patients aged 65 years or older with intravenous BP administration compared to those without was 200.2 (95% CI: 23.8–1679.4, P < 0.001). Patients receiving BP showed a significant association between the incidence of BIONJ and alveolar bone loss score. The risk of ONJ is higher in patients with than without BP administration, particularly intravenous administration. Severe periodontitis might be a risk factor for BIONJ.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Marx R.E.
        Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
        J Oral Maxillofac Surg. 2003; 61: 1115-1117
        • Dimitrakopoulos I.
        • Magopoulos C.
        • Karakasis D.
        Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
        Int J Oral Maxillofac Surg. 2006; 35: 588-593
        • Kos M.
        • Brusco D.
        • Kuebler J.
        • Engelke W.
        Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration.
        Int J Oral Maxillofac Surg. 2010; 39: 1097-1102
        • Hong J.W.
        • Nam W.
        • Cha I.H.
        • Chung S.W.
        • Choi H.S.
        • Kim K.M.
        • et al.
        Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia.
        Osteoporos Int. 2010; 21: 847-853
        • Hoff A.O.
        • Toth B.B.
        • Altundag K.
        • Johnson M.M.
        • Warneke C.L.
        • Hu M.
        • et al.
        Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
        J Bone Miner Res. 2008; 23: 826-836
        • Walter C.
        • Al-Nawas B.
        • Grotz K.A.
        • Thomas C.
        • Thuroff J.W.
        • Zinser V.
        • et al.
        Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
        Eur Urol. 2008; 54: 1066-1072
        • Coleman R.
        • Woodward E.
        • Brown J.
        • Cameron D.
        • Bell R.
        • Dodwell D.
        • et al.
        Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
        Breast Cancer Res Treat. 2011; 127: 429-438
        • Mavrokokki T.
        • Cheng A.
        • Stein B.
        • Goss A.
        Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
        J Oral Maxillofac Surg. 2007; 65: 415-423
        • Sedghizadeh P.P.
        • Stanley K.
        • Caligiuri M.
        • Hofkes S.
        • Lowry B.
        • Shuler C.F.
        Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. An institutional inquiry.
        J Am Dent Assoc. 2009; 140: 61-66
        • Black D.M.
        • Delmas P.D.
        • Eastell R.
        • Reid I.R.
        • Boonen S.
        • Cauley J.A.
        • et al.
        Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
        N Engl J Med. 2007; 356: 1809-1822
        • Wilkinson G.S.
        • Kuo Y.F.
        • Freeman J.L.
        • Goodwin J.S.
        Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.
        J Natl Cancer Inst. 2007; 99: 1016-1024
        • Ruggiero S.L.
        • Mehrotra B.
        • Rosenberg T.J.
        • Engroff S.L.
        Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
        J Oral Maxillofac Surg. 2004; 62: 527-534
        • Woo S.B.
        • Hellstein J.W.
        • Kalmar J.R.
        Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.
        Ann Intern Med. 2006; 144: 753-761
        • Jadu F.
        • Lee L.
        • Pharoah M.
        • Reece D.
        • Wang L.
        A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.
        Ann Oncol. 2007; 18: 2015-2019
        • Vahtsevanos K.
        • Kyrgidis A.
        • Verrou E.
        • Katodritou E.
        • Triaridis S.
        • Andreadis C.G.
        • et al.
        Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
        J Clin Oncol. 2009; 27: 5356-5362
        • Ruggiero S.L.
        • Dodson T.B.
        • Assael L.A.
        • Landesberg R.
        • Marx R.E.
        • Mehrotra B.
        • et al.
        American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update.
        J Oral Maxillofac Surg. 2009; 67: 2-12
        • World health Organization
        Oral health surveys: basic methods.
        4th ed. World health Organization, Geneva1997
        • Shei O.
        Alveolar bone loss as related to oral hygiene and age.
        J Periodontol. 1959; 30: 7-16
        • Engebretson S.P.
        • Lamster I.B.
        • Elkind M.S.
        • Rundek T.
        • Serman N.J.
        • Demmer R.T.
        • et al.
        Radiographic measures of chronic periodontitis and carotid artery plaque.
        Stroke. 2005; 36: 561-566
        • Porta M.
        A dictionary of epidemiology.
        5th ed. Oxford University Press, Oxford2008 (p. 57–58)
        • Fellows J.L.
        • Rindal D.B.
        • Barasch A.
        • Gullion C.M.
        • Rush W.
        • Pihlstrom D.J.
        • et al.
        ONJ in two dental practice-based research network regions.
        J Dent Res. 2011; 90: 433-438
        • Ripamonti C.I.
        • Maniezzo M.
        • Campa T.
        • Fagnoni E.
        • Brunelli C.
        • Saibene G.
        • et al.
        Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.
        Ann Oncol. 2009; 20: 137-145
        • Dimopoulos M.A.
        • Kastritis E.
        • Anagnostopoulos A.
        • Melakopoulos I.
        • Gika D.
        • Moulopoulos L.A.
        • et al.
        Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
        Haematologica. 2006; 91: 968-971
        • Vandone A.M.
        • Donadio M.
        • Mozzati M.
        • Ardine M.
        • Polimeni M.A.
        • Beatrice S.
        • et al.
        Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.
        Ann Oncol. 2012; 23: 193-200
        • Saia G.
        • Blandamura S.
        • Bettini G.
        • Tronchet A.
        • Totola A.
        • Bedogni G.
        • et al.
        Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction.
        J Oral Maxillofac Surg. 2010; 68: 797-804
        • Mawardi H.
        • Giro G.
        • Kajiya M.
        • Ohta K.
        • Almazrooa S.
        • Alshwaimi E.
        • et al.
        A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw.
        J Dent Res. 2011; 90: 1339-1345
        • Cochran D.L.
        Inflammation and bone loss in periodontal disease.
        J Periodontol. 2008; 79: 1569-1576